☰

Yosef Yarden, Ph.D. - Publications

Affiliations: 
Weizmann Institute of Science, Rehovot, Israel 
Area:
Cell Biology, Oncology
Tree Info Grants Similar researchers PubMed Report error

324 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Marrocco I, Yarden Y. Resistance of Lung Cancer to EGFR-Specific Kinase Inhibitors: Activation of Bypass Pathways and Endogenous Mutators. Cancers. 15. PMID 37894376 DOI: 10.3390/cancers15205009  0.352
2023 Marrocco I, Giri S, Simoni-Nieves A, Gupta N, Rudnitsky A, Haga Y, Romaniello D, Sekar A, Zerbib M, Oren R, Lindzen M, Fard D, Tsutsumi Y, Lauriola M, Tamagnone L, ... Yarden Y, et al. L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab. Cell Reports. Medicine. 101142. PMID 37557179 DOI: 10.1016/j.xcrm.2023.101142  0.314
2023 Hedegger K, Blutke A, Hommel T, Auer KE, Nataraj NB, Lindzen M, Yarden Y, Dahlhoff M. Trapping all ERBB ligands decreases pancreatic lesions in a murine model of pancreatic ductal adenocarcinoma. Molecular Oncology. PMID 37341059 DOI: 10.1002/1878-0261.13473  0.375
2022 Nataraj NB, Noronha A, Lee JS, Ghosh S, Mohan Raju HR, Sekar A, Zuckerman B, Lindzen M, Tarcitano E, Srivastava S, Selitrennik M, Livneh I, Drago-Garcia D, Rueda O, Caldas C, ... ... Yarden Y, et al. Nucleoporin-93 reveals a common feature of aggressive breast cancers: robust nucleocytoplasmic transport of transcription factors. Cell Reports. 38: 110418. PMID 35196484 DOI: 10.1016/j.celrep.2022.110418  0.782
2021 Gaviraghi M, Rabellino A, Andolfo A, Brand M, Brombin C, Bagnato P, De Feudis G, Raimondi A, Locatelli A, Tosoni D, Mazza D, Gianni L, Tonon G, Yarden Y, Tacchetti C, et al. Author Correction: Direct stimulation of ERBB2 highlights a novel cytostatic signaling pathway driven by the receptor Thr phosphorylation. Scientific Reports. 11: 18202. PMID 34497338 DOI: 10.1038/s41598-021-97699-1  0.384
2021 Uribe ML, Marrocco I, Yarden Y. EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance. Cancers. 13. PMID 34206026 DOI: 10.3390/cancers13112748  0.412
2021 Uribe ML, Marrocco I, Yarden Y. EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance. Cancers. 13. PMID 34206026 DOI: 10.3390/cancers13112748  0.412
2021 Uribe ML, Dahlhoff M, Batra RN, Nataraj NB, Haga Y, Drago-Garcia D, Marrocco I, Sekar A, Ghosh S, Vaknin I, Lebon S, Kramarski L, Tsutsumi Y, Choi I, Rueda OM, ... ... Yarden Y, et al. TSHZ2 is an EGF-regulated tumor suppressor that binds to the cytokinesis regulator PRC1 and inhibits metastasis. Science Signaling. 14. PMID 34158398 DOI: 10.1126/scisignal.abe6156  0.316
2020 Gaviraghi M, Rabellino A, Andolfo A, Brand M, Brombin C, Bagnato P, De Feudis G, Raimondi A, Locatelli A, Tosoni D, Mazza D, Gianni L, Tonon G, Yarden Y, Tacchetti C, et al. Direct stimulation of ERBB2 highlights a novel cytostatic signaling pathway driven by the receptor Thr phosphorylation. Scientific Reports. 10: 16906. PMID 33037285 DOI: 10.1038/s41598-020-73835-1  0.501
2020 Shenoy A, Belugali Nataraj N, Perry G, Loayza Puch F, Nagel R, Marin I, Balint N, Bossel N, Pavlovsky A, Barshack I, Kaufman B, Agami R, Yarden Y, Dadiani M, Geiger T. Proteomic patterns associated with response to breast cancer neoadjuvant treatment. Molecular Systems Biology. 16: e9443. PMID 32960509 DOI: 10.15252/Msb.20209443  0.305
2020 Romaniello D, Marrocco I, Belugali Nataraj N, Ferrer I, Drago-Garcia D, Vaknin I, Oren R, Lindzen M, Ghosh S, Kreitman M, Kittel JC, Gaborit N, Bergado Baez G, Sanchez B, Eilam R, ... ... Yarden Y, et al. Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor. Cancers. 12. PMID 32847130 DOI: 10.3390/Cancers12092394  0.486
2020 Ghosh S, Marrocco I, Yarden Y. Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment. Advances in Cancer Research. 147: 1-57. PMID 32593398 DOI: 10.1016/Bs.Acr.2020.04.002  0.514
2019 Bousquet Mur E, Bernardo S, Papon L, Mancini M, Fabbrizio E, Goussard M, Ferrer I, Giry A, Quantin X, Pujol JL, Calvayrac O, Moll HP, Glasson Y, Pirot N, Turtoi A, ... ... Yarden Y, et al. Notch inhibition overcomes resistance to Tyrosine Kinase Inhibitors in EGFR-driven lung adenocarcinoma. The Journal of Clinical Investigation. PMID 31671073 DOI: 10.1172/Jci126896  0.397
2019 Srivastava S, Nataraj NB, Sekar A, Ghosh S, Bornstein C, Drago-Garcia D, Roth L, Romaniello D, Marrocco I, David E, Gilad Y, Lauriola M, Rotkopf R, Kimchi A, Haga Y, ... ... Yarden Y, et al. ETS Proteins Bind with Glucocorticoid Receptors: Relevance for Treatment of Ewing Sarcoma. Cell Reports. 29: 104-117.e4. PMID 31577941 DOI: 10.1016/J.Celrep.2019.08.088  0.464
2019 Maron R, Schechter B, Nataraj NB, Ghosh S, Romaniello D, Marrocco I, Noronha A, Carvalho S, Yarden Y, Sela M. Inhibition of a pancreatic cancer model by cooperative pairs of clinically approved and experimental antibodies. Biochemical and Biophysical Research Communications. PMID 30952434 DOI: 10.1016/J.Bbrc.2019.03.204  0.458
2019 Kubli SP, Bassi C, Roux C, Wakeham A, Göbl C, Zhou W, Jafari SM, Snow B, Jones L, Palomero L, Thu KL, Cassetta L, Soong D, Berger T, Ramachandran P, ... ... Yarden Y, et al. AhR controls redox homeostasis and shapes the tumor microenvironment in BRCA1-associated breast cancer. Proceedings of the National Academy of Sciences of the United States of America. PMID 30733286 DOI: 10.1073/Pnas.1815126116  0.475
2019 Marrocco I, Romaniello D, Yarden Y. Cancer Immunotherapy: The Dawn of Antibody Cocktails. Methods in Molecular Biology (Clifton, N.J.). 1904: 11-51. PMID 30539465 DOI: 10.1007/978-1-4939-8958-4_2  0.337
2018 Romaniello D, Mazzeo L, Mancini M, Marrocco I, Noronha A, Kreitman MS, Srivastava S, Ghosh S, Lindzen M, Salame TM, Onn A, Bar J, Yarden Y. A Combination Of Approved Antibodies Overcomes Resistance Of Lung Cancer To Osimertinib By Blocking Bypass Pathways. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29967248 DOI: 10.1158/1078-0432.Ccr-18-0450  0.36
2018 Arandkar S, Furth N, Elisha Y, Nataraj NB, van der Kuip H, Yarden Y, Aulitzky W, Ulitsky I, Geiger B, Oren M. Altered p53 functionality in cancer-associated fibroblasts contributes to their cancer-supporting features. Proceedings of the National Academy of Sciences of the United States of America. PMID 29866855 DOI: 10.1073/Pnas.1719076115  0.314
2018 Kreitman M, Noronha A, Yarden Y. Irreversible Modifications of Receptor Tyrosine Kinases. Febs Letters. PMID 29790151 DOI: 10.1002/1873-3468.13095  0.586
2018 Claus J, Patel G, Autore F, Colomba A, Weitsman G, Soliman TN, Roberts S, Zanetti-Domingues LC, Hirsch M, Collu F, George R, Ortiz-Zapater E, Barber PR, Vojnovic B, Yarden Y, et al. Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface. Elife. 7. PMID 29712619 DOI: 10.7554/Elife.32271  0.449
2018 Roth L, Srivastava S, Lindzen M, Sas-Chen A, Sheffer M, Lauriola M, Enuka Y, Noronha A, Mancini M, Lavi S, Tarcic G, Pines G, Nevo N, Heyman O, Ziv T, ... ... Yarden Y, et al. SILAC identifies LAD1 as a filamin-binding regulator of actin dynamics in response to EGF and a marker of aggressive breast tumors. Science Signaling. 11. PMID 29382783 DOI: 10.1126/Scisignal.Aan0949  0.463
2018 Claus J, Patel G, Autore F, Colomba A, Weitsman G, Soliman TN, Roberts S, Zanetti-Domingues LC, Hirsch M, Collu F, George R, Ortiz-Zapater E, Barber PR, Vojnovic B, Yarden Y, et al. Author response: Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface Elife. DOI: 10.7554/Elife.32271.037  0.337
2017 Mancini M, Gal H, Gaborit N, Mazzeo L, Romaniello D, Salame TM, Lindzen M, Mahlknecht G, Enuka Y, Burton DG, Roth L, Noronha A, Marrocco I, Adreka D, Altstadter RE, ... ... Yarden Y, et al. An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors. Embo Molecular Medicine. PMID 29212784 DOI: 10.15252/Emmm.201708076  0.624
2017 Enuka Y, Feldman ME, Chowdhury A, Srivastava S, Lindzen M, Sas-Chen A, Massart R, Cheishvili D, Suderman MJ, Zaltsman Y, Mazza CA, Shukla K, Körner C, Furth N, Lauriola M, ... ... Yarden Y, et al. Epigenetic mechanisms underlie the crosstalk between growth factors and a steroid hormone. Nucleic Acids Research. PMID 29036586 DOI: 10.1093/Nar/Gkx865  0.377
2017 Dahlhoff M, Gaborit N, Bultmann S, Leonhardt H, Yarden Y, Schneider MR. CRISPR-assisted receptor deletion reveals distinct roles for ERBB2 and ERBB3 in skin keratinocytes. The Febs Journal. PMID 28805349 DOI: 10.1111/Febs.14196  0.486
2017 Golan-Lavi R, Giacomelli C, Fuks G, Zeisel A, Sonntag J, Sinha S, Köstler W, Wiemann S, Korf U, Yarden Y, Domany E. Coordinated Pulses of mRNA and of Protein Translation or Degradation Produce EGF-Induced Protein Bursts. Cell Reports. 18: 3129-3142. PMID 28355565 DOI: 10.1016/J.Celrep.2017.03.014  0.313
2017 Sas-Chen A, Srivastava S, Yarden Y. The short and the long: non-coding RNAs and growth factors in cancer progression. Biochemical Society Transactions. 45: 51-64. PMID 28202659 DOI: 10.1042/Bst20160131  0.302
2017 Tarcic O, Granit RZ, Pateras IS, Masury H, Maly B, Zwang Y, Yarden Y, Gorgoulis VG, Pikarsky E, Ben-Porath I, Oren M. RNF20 and histone H2B ubiquitylation exert opposing effects in Basal-Like versus luminal breast cancer. Cell Death and Differentiation. PMID 28157208 DOI: 10.1038/Cdd.2016.126  0.739
2016 Gelfo V, Rodia MT, Pucci M, Dall'Ora M, Santi S, Solmi R, Roth L, Lindzen M, Bonafè M, Bertotti A, Caramelli E, Lollini PL, Trusolino L, Yarden Y, D'Uva G, et al. A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors. Oncotarget. PMID 27708224 DOI: 10.18632/Oncotarget.12354  0.406
2016 Bublil EM, Cohen T, Arnusch CJ, Peleg A, Pines G, Lavi S, Yarden Y, Shai Y. Interfering with the Dimerization of the ErbB Receptors by Transmembrane Domain Derived Peptides Inhibits Tumorigenic Growth in Vitro and In Vivo. Biochemistry. PMID 27575020 DOI: 10.1021/Acs.Biochem.6B00450  0.512
2016 Sas-Chen A, Aure MR, Leibovich L, Carvalho S, Enuka Y, Körner C, Polycarpou-Schwarz M, Lavi S, Nevo N, Kuznetsov Y, Yuan J, Azuaje F, Ulitsky I, Diederichs S, ... ... Yarden Y, et al. LIMT is a novel metastasis inhibiting lncRNA suppressed by EGF and downregulated in aggressive breast cancer. Embo Molecular Medicine. PMID 27485121 DOI: 10.15252/Emmm.201606198  0.42
2016 Tóth G, Szöőr Á, Simon L, Yarden Y, Szöllősi J, Vereb G. The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity. Mabs. 0. PMID 27380003 DOI: 10.1080/19420862.2016.1204503  0.321
2016 Grossman M, Ben-Chetrit N, Zhuravlev A, Afik R, Bassat E, Solomonov I, Yarden Y, Sagi I. Tumor cell invasion can be blocked by modulators of collagen fibril alignment that control assembly of the extracellular matrix. Cancer Research. PMID 27221706 DOI: 10.1158/0008-5472.Can-15-2813  0.315
2016 Carvalho S, Levi-Schaffer F, Sela M, Yarden Y. Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review X. British Journal of Pharmacology. PMID 26833433 DOI: 10.1111/Bph.13450  0.351
2016 Donzelli S, Cioce M, Muti P, Strano S, Yarden Y, Blandino G. MicroRNAs: Non-coding fine tuners of receptor tyrosine kinase signalling in cancer. Seminars in Cell & Developmental Biology. PMID 26773212 DOI: 10.1016/J.Semcdb.2015.12.020  0.463
2016 Zhu G, Saboor-Yaraghi A, Yarden Y, Santos J, JC N. Downregulating oncogenic receptor: From bench to clinic Hematology & Medical Oncology. 1. DOI: 10.15761/HMO.1000106  0.319
2016 Tóth G, Szöőr Á, Simon L, Yarden Y, Szöllősi J, Vereb G. Abstract B069: The best is not enough—when it is alone: Current clinical doses of humanized anti-Her2 antibodies should be applied in combination to delay development of trastuzumab resistance by additively enhancing ADCC Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-B069  0.317
2015 Enuka Y, Lauriola M, Feldman ME, Sas-Chen A, Ulitsky I, Yarden Y. Circular RNAs are long-lived and display only minimal early alterations in response to a growth factor. Nucleic Acids Research. PMID 26657629 DOI: 10.1093/Nar/Gkv1367  0.323
2015 Gaborit N, Lindzen M, Yarden Y. Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3. Human Vaccines & Immunotherapeutics. 1-17. PMID 26529100 DOI: 10.1080/21645515.2015.1102809  0.453
2015 Schneider MR, Yarden Y. The EGFR-HER2 module: a stem cell approach to understanding a prime target and driver of solid tumors. Oncogene. PMID 26434585 DOI: 10.1038/Onc.2015.372  0.467
2015 Mancini M, Yarden Y. Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors. Seminars in Cell & Developmental Biology. PMID 26428295 DOI: 10.1016/J.Semcdb.2015.09.018  0.416
2015 Kedmi M, Sas-Chen A, Yarden Y. MicroRNAs and Growth Factors: An Alliance Propelling Tumor Progression. Journal of Clinical Medicine. 4: 1578-99. PMID 26287249 DOI: 10.3390/Jcm4081578  0.438
2015 Mahlknecht G, Maron R, Schechter B, Yarden Y, Sela M. Multimerization of ERBB2/HER2 specific aptamer leads to improved receptor binding. Biochemical and Biophysical Research Communications. 465: 218-24. PMID 26248137 DOI: 10.1016/J.Bbrc.2015.07.157  0.395
2015 Capparelli C, Rosenbaum S, Berman-Booty LD, Salhi A, Gaborit N, Zhan T, Chervoneva I, Roszik J, Woodman SE, Davies MA, Setiady YY, Osman I, Yarden Y, Aplin AE. ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas. Cancer Research. 75: 3554-67. PMID 26206558 DOI: 10.1158/0008-5472.Can-14-2959  0.458
2015 Mahlknecht G, Sela M, Yarden Y. Aptamer Targeting the ERBB2 Receptor Tyrosine Kinase for Applications in Tumor Therapy. Methods in Molecular Biology (Clifton, N.J.). 1317: 3-15. PMID 26072398 DOI: 10.1007/978-1-4939-2727-2_1  0.437
2015 Mancini M, Gaborit N, Lindzen M, Salame TM, Dall'Ora M, Sevilla-Sharon M, Abdul-Hai A, Downward J, Yarden Y. Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer. Science Signaling. 8: ra53. PMID 26038598 DOI: 10.1126/Scisignal.Aaa0725  0.687
2015 Yarden Y, Sela M. Cancer Immunotherapy: More Is (Much) Better. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 4030-2. PMID 26019173 DOI: 10.1158/1078-0432.Ccr-15-0996  0.34
2015 Carvalho S, Lindzen M, Lauriola M, Shirazi N, Sinha S, Abdul-Hai A, Levanon K, Korach J, Barshack I, Cohen Y, Onn A, Mills G, Yarden Y. An antibody to amphiregulin, an abundant growth factor in patients' fluids, inhibits ovarian tumors. Oncogene. PMID 25915843 DOI: 10.1038/Onc.2015.93  0.48
2015 D'Uva G, Aharonov A, Lauriola M, Kain D, Yahalom-Ronen Y, Carvalho S, Weisinger K, Bassat E, Rajchman D, Yifa O, Lysenko M, Konfino T, Hegesh J, Brenner O, Neeman M, ... Yarden Y, et al. ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation. Nature Cell Biology. 17: 627-38. PMID 25848746 DOI: 10.1038/Ncb3149  0.325
2015 Kedmi M, Ben-Chetrit N, Körner C, Mancini M, Ben-Moshe NB, Lauriola M, Lavi S, Biagioni F, Carvalho S, Cohen-Dvashi H, Schmitt F, Wiemann S, Blandino G, Yarden Y. EGF induces microRNAs that target suppressors of cell migration: miR-15b targets MTSS1 in breast cancer. Science Signaling. 8: ra29. PMID 25783158 DOI: 10.1126/Scisignal.2005866  0.748
2015 Cohen-Dvashi H, Ben-Chetrit N, Russell R, Carvalho S, Lauriola M, Nisani S, Mancini M, Nataraj N, Kedmi M, Roth L, Köstler W, Zeisel A, Yitzhaky A, Zylberg J, Tarcic G, ... ... Yarden Y, et al. Navigator-3, a modulator of cell migration, may act as a suppressor of breast cancer progression. Embo Molecular Medicine. 7: 299-314. PMID 25678558 DOI: 10.15252/Emmm.201404134  0.771
2015 Ben-Chetrit N, Chetrit D, Russell R, Körner C, Mancini M, Abdul-Hai A, Itkin T, Carvalho S, Cohen-Dvashi H, Koestler WJ, Shukla K, Lindzen M, Kedmi M, Lauriola M, Shulman Z, ... ... Yarden Y, et al. Synaptojanin 2 is a druggable mediator of metastasis and the gene is overexpressed and amplified in breast cancer. Science Signaling. 8: ra7. PMID 25605973 DOI: 10.1126/Scisignal.2005537  0.776
2015 Gaborit N, Abdul-Hai A, Mancini M, Lindzen M, Lavi S, Leitner O, Mounier L, Chentouf M, Dunoyer S, Ghosh M, Larbouret C, Chardès T, Bazin H, Pèlegrin A, Sela M, ... Yarden Y, et al. Examination of HER3 targeting in cancer using monoclonal antibodies. Proceedings of the National Academy of Sciences of the United States of America. 112: 839-44. PMID 25564668 DOI: 10.1073/Pnas.1423645112  0.483
2015 Rosenbaum S, Capparelli C, Berman-Booty LD, Gaborit N, Zhan T, Davies MA, Setiady YY, Yarden Y, Aplin AE. Abstract A52: Extracellular matrix regulation of ErbB3 in a subset of wild-type BRAF/NRAS melanoma Molecular Cancer Therapeutics. 14. DOI: 10.1158/1538-8514.Pi3K14-A52  0.512
2015 Capparelli C, Rosenbaum S, Berman-Booty LD, Gaborit N, Zhan T, Davies MA, Setiady YY, Yarden Y, Aplin AE. Abstract A09: ErbB3/ErbB2 complexes as a therapeutic target in a subset of wild-type BRAF/NRAS cutaneous melanomas Cancer Research. 75. DOI: 10.1158/1538-7445.Mel2014-A09  0.459
2015 Lauriola M, Enuka Y, Zeisel A, D'Uva G, Roth L, Carvalho S, Solmi R, Domany E, Yarden Y. Abstract 3475: Diurnal suppression of EGFR signaling by glucocorticoids: implications for tumor progression and treatment Cancer Research. 75: 3475-3475. DOI: 10.1158/1538-7445.Am2015-3475  0.543
2015 Lindzen M, Carvalho S, Yarden Y. Abstract A58: Antibodies to amphiregulin, an abundant growth factor in patients' fluids, inhibits tumor growth Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-A58  0.436
2015 Köstler WJ, Yarden Y. HER Molecular Oncology: Causes of Cancer and Targets For Treatment. 85-109. DOI: 10.1017/CBO9781139046947.011  0.515
2015 Pareja F, Pines G, Yarden Y. The EGFR/ERBB receptor family Receptor Tyrosine Kinases: Family and Subfamilies. 107-164. DOI: 10.1007/978-3-319-11888-8_4  0.509
2015 Mahlknecht G, Sela M, Yarden Y. Aptamer targeting the ERBB2 receptor tyrosine kinase for applications in tumor therapy Methods in Molecular Biology. 1317: 3-15. DOI: 10.1007/978-1-4939-2727-2_1  0.355
2015 Wheeler DL, Yarden Y. Receptor tyrosine kinases: Structure, functions and role in human disease Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease. 1-440. DOI: 10.1007/978-1-4939-2053-2  0.355
2014 Lauriola M, Enuka Y, Zeisel A, D'Uva G, Roth L, Sharon-Sevilla M, Lindzen M, Sharma K, Nevo N, Feldman M, Carvalho S, Cohen-Dvashi H, Kedmi M, Ben-Chetrit N, Chen A, ... ... Yarden Y, et al. Diurnal suppression of EGFR signalling by glucocorticoids and implications for tumour progression and treatment. Nature Communications. 5: 5073. PMID 25278152 DOI: 10.1038/Ncomms6073  0.811
2014 Kiuchi T, Ortiz-Zapater E, Monypenny J, Matthews DR, Nguyen LK, Barbeau J, Coban O, Lawler K, Burford B, Rolfe DJ, de Rinaldis E, Dafou D, Simpson MA, Woodman N, Pinder S, ... ... Yarden Y, et al. The ErbB4 CYT2 variant protects EGFR from ligand-induced degradation to enhance cancer cell motility. Science Signaling. 7: ra78. PMID 25140053 DOI: 10.1126/Scisignal.2005157  0.462
2014 Feldman ME, Yarden Y. Steering tumor progression through the transcriptional response to growth factors and stroma. Febs Letters. 588: 2407-14. PMID 24873881 DOI: 10.1016/J.Febslet.2014.05.036  0.377
2014 Burgess AW, Henis YI, Hynes NE, Jovin T, Levitzki A, Pinkas-Kramarski R, Yarden Y. EGF receptor family: twisting targets for improved cancer therapies. Growth Factors (Chur, Switzerland). 32: 74-81. PMID 24641597 DOI: 10.3109/08977194.2014.896355  0.543
2014 Schneider MR, Yarden Y. Structure and function of epigen, the last EGFR ligand. Seminars in Cell & Developmental Biology. 28: 57-61. PMID 24374012 DOI: 10.1016/J.Semcdb.2013.12.011  0.501
2013 Köstler WJ, Zeisel A, Körner C, Tsai JM, Jacob-Hirsch J, Ben-Chetrit N, Sharma K, Cohen-Dvashi H, Yitzhaky A, Lader E, Tschulena U, Rechavi G, Domany E, Wiemann S, Yarden Y. Epidermal growth-factor-induced transcript isoform variation drives mammary cell migration. Plos One. 8: e80566. PMID 24324612 DOI: 10.1371/Journal.Pone.0080566  0.785
2013 Mellman I, Yarden Y. Endocytosis and cancer. Cold Spring Harbor Perspectives in Biology. 5: a016949. PMID 24296170 DOI: 10.1101/Cshperspect.A016949  0.451
2013 D'Uva G, Bertoni S, Lauriola M, De Carolis S, Pacilli A, D'Anello L, Santini D, Taffurelli M, Ceccarelli C, Yarden Y, Montanaro L, Bonafé M, Storci G. Beta-catenin/HuR post-transcriptional machinery governs cancer stem cell features in response to hypoxia. Plos One. 8: e80742. PMID 24260469 DOI: 10.1371/Journal.Pone.0080742  0.309
2013 Maron R, Schechter B, Mancini M, Mahlknecht G, Yarden Y, Sela M. Inhibition of pancreatic carcinoma by homo-and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2 Proceedings of the National Academy of Sciences of the United States of America. 110: 15389-15394. PMID 24003140 DOI: 10.1073/Pnas.1313857110  0.517
2013 Mahlknecht G, Maron R, Mancini M, Schechter B, Sela M, Yarden Y. Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth Proceedings of the National Academy of Sciences of the United States of America. 110: 8170-8175. PMID 23630281 DOI: 10.1073/Pnas.1302594110  0.469
2013 Ferraro DA, Gaborit N, Maron R, Cohen-Dvashi H, Porat Z, Pareja F, Lavi S, Lindzen M, Ben-Chetrit N, Sela M, Yarden Y. Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR Proceedings of the National Academy of Sciences of the United States of America. 110: 1815-1820. PMID 23319610 DOI: 10.1073/Pnas.1220763110  0.808
2013 Ben-Chetrit N, Tarcic G, Yarden Y. ERK-ERF-EGR1, a novel switch underlying acquisition of a motile phenotype. Cell Adhesion & Migration. 7: 33-7. PMID 23076209 DOI: 10.4161/Cam.22263  0.448
2013 Zeisel A, Yitzhaky A, Koerner C, Lauriola M, Cohen-Dvashi H, Köstler WJ, Yarden Y, Wiemann S, Domany E. qCMA: a desktop application for quantitative collective cell migration analysis. Journal of Biomolecular Screening. 18: 356-60. PMID 23042078 DOI: 10.1177/1087057112461940  0.706
2013 Barnea I, Haif S, Keshet R, Karaush V, Lev-Ari S, Khafif A, Shtabsky A, Yarden Y, Vexler A, Ben Yosef R. Targeting ErbB-1 and ErbB-4 in irradiated head and neck cancer: results of in vitro and in vivo studies. Head & Neck. 35: 399-407. PMID 22367849 DOI: 10.1002/Hed.22967  0.371
2013 Ben-Chetrit N, Chetrit D, Koerner C, Carvalho S, Symons M, Schmitt F, Wiemann S, Ehrlich M, Yarden Y. Abstract A84: Synaptojanin-2 and microRNA-31 control invadopodia and metastasis by regulating vesicular trafficking Cancer Research. 73. DOI: 10.1158/1538-7445.Tim2013-A84  0.388
2013 Capparelli C, Gaborit N, Yarden Y, Aplin A. Abstract C44: Targeting neuregulin1-ErbB3 signaling in wild-type BRAF/NRAS melanoma. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C44  0.475
2012 Biagioni F, Bossel Ben-Moshe N, Fontemaggi G, Canu V, Mori F, Antoniani B, Di Benedetto A, Santoro R, Germoni S, De Angelis F, Cambria A, Avraham R, Grasso G, Strano S, Muti P, ... ... Yarden Y, et al. miR-10b*, a master inhibitor of the cell cycle, is down-regulated in human breast tumours. Embo Molecular Medicine. 4: 1214-29. PMID 23125021 DOI: 10.1002/Emmm.201201483  0.319
2012 Yarden Y, Pines G. The ERBB network: at last, cancer therapy meets systems biology. Nature Reviews. Cancer. 12: 553-63. PMID 22785351 DOI: 10.1038/Nrc3309  0.354
2012 Zwang Y, Oren M, Yarden Y. Consistency test of the cell cycle: roles for p53 and EGR1. Cancer Research. 72: 1051-4. PMID 22315347 DOI: 10.1158/0008-5472.Can-11-3382  0.736
2012 Avraham R, Yarden Y. Regulation of signalling by microRNAs. Biochemical Society Transactions. 40: 26-30. PMID 22260661 DOI: 10.1042/Bst20110623  0.328
2012 Tarcic G, Avraham R, Pines G, Amit I, Shay T, Lu Y, Zwang Y, Katz M, Ben-Chetrit N, Jacob-Hirsch J, Virgilio L, Rechavi G, Mavrothalassitis G, Mills GB, Domany E, ... Yarden Y, et al. EGR1 and the ERK-ERF axis drive mammary cell migration in response to EGF. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 26: 1582-92. PMID 22198386 DOI: 10.1096/Fj.11-194654  0.784
2012 Pareja F, Ferraro DA, Rubin C, Cohen-Dvashi H, Zhang F, Aulmann S, Ben-Chetrit N, Pines G, Navon R, Crosetto N, Köstler W, Carvalho S, Lavi S, Schmitt F, Dikic I, ... ... Yarden Y, et al. Deubiquitination of EGFR by Cezanne-1 contributes to cancer progression. Oncogene. 31: 4599-608. PMID 22179831 DOI: 10.1038/Onc.2011.587  0.851
2012 Pradeep CR, Zeisel A, Köstler WJ, Lauriola M, Jacob-Hirsch J, Haibe-Kains B, Amariglio N, Ben-Chetrit N, Emde A, Solomonov I, Neufeld G, Piccart M, Sagi I, Sotiriou C, Rechavi G, ... ... Yarden Y, et al. Modeling invasive breast cancer: Growth factors propel progression of HER2-positive premalignant lesions Oncogene. 31: 3569-3583. PMID 22139081 DOI: 10.1038/Onc.2011.547  0.508
2012 Lindzen M, Carvalho S, Starr A, Ben-Chetrit N, Pradeep CR, Köstler WJ, Rabinkov A, Lavi S, Bacus SS, Yarden Y. A recombinant decoy comprising EGFR and ErbB-4 inhibits tumor growth and metastasis. Oncogene. 31: 3505-15. PMID 22105361 DOI: 10.1038/Onc.2011.518  0.514
2012 Pradeep CR, Köstler WJ, Lauriola M, Granit RZ, Zhang F, Jacob-Hirsch J, Rechavi G, Nair HB, Hennessy BT, Gonzalez-Angulo AM, Tekmal RR, Ben-Porath I, Mills GB, Domany E, Yarden Y. Modeling ductal carcinoma in situ: a HER2-Notch3 collaboration enables luminal filling. Oncogene. 31: 907-17. PMID 21743488 DOI: 10.1038/Onc.2011.279  0.413
2012 Emde A, Köstler WJ, Yarden Y. Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer. Critical Reviews in Oncology/Hematology. 84: e49-57. PMID 20951604 DOI: 10.1016/J.Critrevonc.2010.09.002  0.488
2012 Yarden Y. Abstract BL-1: Brinker Award Lecture: How Does HER2 Contribute to Breast Cancer Progression? Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-Bl-1  0.605
2011 Emde A, Mahlknecht G, Maslak K, Ribba B, Sela M, Possinger K, Yarden Y. Simultaneous Inhibition of Estrogen Receptor and the HER2 Pathway in Breast Cancer: Effects of HER2 Abundance. Translational Oncology. 4: 293-300. PMID 21966546 DOI: 10.1593/Tlo.11127  0.489
2011 Witsch EJ, Mahlknecht G, Wakim J, Sertchook R, Bublil E, Yarden Y, Sela M. Generation and characterization of peptide mimotopes specific for anti erbb-2 monoclonal antibodies International Immunology. 23: 391-403. PMID 21602175 DOI: 10.1093/Intimm/Dxr028  0.309
2011 Zwang Y, Sas-Chen A, Drier Y, Shay T, Avraham R, Lauriola M, Shema E, Lidor-Nili E, Jacob-Hirsch J, Amariglio N, Lu Y, Mills GB, Rechavi G, Oren M, Domany E, ... Yarden Y, et al. Two phases of mitogenic signaling unveil roles for p53 and EGR1 in elimination of inconsistent growth signals. Molecular Cell. 42: 524-35. PMID 21596316 DOI: 10.1016/J.Molcel.2011.04.017  0.741
2011 Yarden Y. The biological framework: translational research from bench to clinic. The Oncologist. 16: 23-9. PMID 21278438 DOI: 10.1634/Theoncologist.2011-S1-23  0.413
2011 Avraham R, Yarden Y. Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nature Reviews. Molecular Cell Biology. 12: 104-17. PMID 21252999 DOI: 10.1038/Nrm3048  0.515
2011 Emde A, Pradeep CR, Ferraro DA, Ben-Chetrit N, Sela M, Ribba B, Kam Z, Yarden Y. Combining epitope-distinct antibodies to HER2: Cooperative inhibitory effects on invasive growth Oncogene. 30: 1631-1642. PMID 21132012 DOI: 10.1038/Onc.2010.547  0.403
2011 Yarden Y, Pareja F. Abstract SY23-02: RTK endocytosis and other feedback mechanisms in cancer Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Sy23-02  0.547
2011 Pradeep C, Koestler W, Lauriola M, Nair H, Rao R, Mills G, Yarden Y. P2-03-04: Novel Pathways Underlying the Initiation and Transition of DCIS to IDC of HER2−Overexpressing Breast Cancer Model. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P2-03-04  0.417
2011 Köstler WJ, Yarden Y. The EGFR/ErbB family in breast cancer: From signalling to therapy Milestones in Drug Therapy. 38: 1-32. DOI: 10.1007/978-3-0346-0094-1_1  0.369
2010 Tarcic G, Yarden Y. MAP Kinase activation by receptor tyrosine kinases: in control of cell migration. Methods in Molecular Biology (Clifton, N.J.). 661: 125-35. PMID 20811980 DOI: 10.1007/978-1-60761-795-2_7  0.56
2010 Bublil EM, Pines G, Patel G, Fruhwirth G, Ng T, Yarden Y. Kinase-mediated quasi-dimers of EGFR. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 24: 4744-55. PMID 20682838 DOI: 10.1096/Fj.10-166199  0.54
2010 Pines G, Huang PH, Zwang Y, White FM, Yarden Y. EGFRvIV: a previously uncharacterized oncogenic mutant reveals a kinase autoinhibitory mechanism. Oncogene. 29: 5850-60. PMID 20676128 DOI: 10.1038/Onc.2010.313  0.814
2010 Spangler JB, Neil JR, Abramovitch S, Yarden Y, White FM, Lauffenburger DA, Wittrup KD. Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. Proceedings of the National Academy of Sciences of the United States of America. 107: 13252-7. PMID 20616078 DOI: 10.1073/Pnas.0913476107  0.572
2010 Lindzen M, Lavi S, Leitner O, Yarden Y. Tailored cancer immunotherapy using combinations of chemotherapy and a mixture of antibodies against EGF-receptor ligands. Proceedings of the National Academy of Sciences of the United States of America. 107: 12559-63. PMID 20616021 DOI: 10.1073/Pnas.1006218107  0.459
2010 Avraham R, Sas-Chen A, Manor O, Steinfeld I, Shalgi R, Tarcic G, Bossel N, Zeisel A, Amit I, Zwang Y, Enerly E, Russnes HG, Biagioni F, Mottolese M, Strano S, ... ... Yarden Y, et al. EGF decreases the abundance of microRNAs that restrain oncogenic transcription factors. Science Signaling. 3: ra43. PMID 20516477 DOI: 10.1126/Scisignal.2000876  0.783
2010 Witsch E, Sela M, Yarden Y. Roles for Growth Factors in Cancer Progression Physiology. 25: 85-101. PMID 20430953 DOI: 10.1152/Physiol.00045.2009  0.42
2010 Pines G, Köstler WJ, Yarden Y. Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy. Febs Letters. 584: 2699-706. PMID 20388509 DOI: 10.1016/J.Febslet.2010.04.019  0.549
2010 Mills GB, Yarden Y. The rebirth of a phoenix: ovarian cancers are addicted to ErbB-3. Cancer Cell. 17: 217-8. PMID 20227035 DOI: 10.1016/J.Ccr.2010.02.023  0.371
2010 Köstler WJ, Yarden Y. The epidermal growth factor receptor family Handbook of Cell Signaling, 2/E. 2: 435-441. DOI: 10.1016/B978-0-12-374145-5.00061-9  0.548
2009 Tarcic G, Boguslavsky SK, Wakim J, Kiuchi T, Liu A, Reinitz F, Nathanson D, Takahashi T, Mischel PS, Ng T, Yarden Y. An unbiased screen identifies DEP-1 tumor suppressor as a phosphatase controlling EGFR endocytosis. Current Biology : Cb. 19: 1788-98. PMID 19836242 DOI: 10.1016/J.Cub.2009.09.048  0.523
2009 Mills GB, Jurisica I, Yarden Y, Norman JC. Genomic amplicons target vesicle recycling in breast cancer. The Journal of Clinical Investigation. 119: 2123-7. PMID 19620778 DOI: 10.1172/Jci40256  0.383
2009 Mosesson Y, Chetrit D, Schley L, Berghoff J, Ziv T, Carvalho S, Milanezi F, Admon A, Schmitt F, Ehrlich M, Yarden Y. Monoubiquitinylation regulates endosomal localization of Lst2, a negative regulator of EGF receptor signaling. Developmental Cell. 16: 687-98. PMID 19460345 DOI: 10.1016/J.Devcel.2009.03.015  0.551
2009 Ben-Kasus T, Schechter B, Lavi S, Yarden Y, Sela M. Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis Proceedings of the National Academy of Sciences of the United States of America. 106: 3294-3299. PMID 19218427 DOI: 10.1073/Pnas.0812059106  0.405
2009 Zwang Y, Yarden Y. Systems biology of growth factor-induced receptor endocytosis. Traffic (Copenhagen, Denmark). 10: 349-63. PMID 19183301 DOI: 10.1111/J.1600-0854.2008.00870.X  0.813
2009 Schechter B, Ben-Kasus T, Yarden Y, Sela M. On the notion of synergy of monoclonal antibodies as drugs Communicative and Integrative Biology. 2: 477-478. DOI: 10.4161/Cib.2.6.9326  0.506
2009 Chaluvally-Raghavan P, Zeisel A, Koestler W, Jacob-Hirsch J, Rechavi G, Domany E, Yarden Y. HER2-Associated Breast Cancer Signature Using a 3D Culture Model. Cancer Research. 69: 4146-4146. DOI: 10.1158/0008-5472.Sabcs-09-4146  0.372
2008 Mosesson Y, Mills GB, Yarden Y. Derailed endocytosis: an emerging feature of cancer. Nature Reviews. Cancer. 8: 835-50. PMID 18948996 DOI: 10.1038/Nrc2521  0.487
2008 Seger R, Rodeck U, Yarden Y. Meeting report: Receptor tyrosine kinases: The emerging tip of systems control Iet Systems Biology. 2: 1-4. DOI: 10.1049/Iet-Syb:20070048  0.504
2008 Yarden Y. The EGF receptor signalling system European Journal of Cancer Supplements. 6: 1. DOI: 10.1016/S1359-6349(08)71177-7  0.496
2008 Yarden Y, Schlessinger J. The EGF receptor kinase: Evidence for allosteric activation and intramolecular self-phosphorylation Growth Factors in Biology and Medicine. 23-45. DOI: 10.1002/9780470720974.ch3  0.653
2007 Ben-Kasus T, Schechter B, Sela M, Yarden Y. Cancer therapeutic antibodies come of age: Targeting minimal residual disease Molecular Oncology. 1: 42-54. PMID 19383286 DOI: 10.1016/J.Molonc.2007.01.003  0.324
2007 Amit I, Wides R, Yarden Y. Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy. Molecular Systems Biology. 3: 151. PMID 18059446 DOI: 10.1038/Msb4100195  0.447
2007 Yarden Y, Shilo BZ. SnapShot: EGFR signaling pathway. Cell. 131: 1018. PMID 18045542 DOI: 10.1016/J.Cell.2007.11.013  0.396
2007 Katz M, Amit I, Citri A, Shay T, Carvalho S, Lavi S, Milanezi F, Lyass L, Amariglio N, Jacob-Hirsch J, Ben-Chetrit N, Tarcic G, Lindzen M, Avraham R, Liao YC, ... ... Yarden Y, et al. A reciprocal tensin-3-cten switch mediates EGF-driven mammary cell migration. Nature Cell Biology. 9: 961-9. PMID 17643115 DOI: 10.1038/Ncb1622  0.757
2007 Spector NL, Yarden Y, Smith B, Lyass L, Trusk P, Pry K, Hill JE, Xia W, Seger R, Bacus SS. Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells. Proceedings of the National Academy of Sciences of the United States of America. 104: 10607-12. PMID 17556544 DOI: 10.1073/Pnas.0701286104  0.505
2007 Sundvall M, Peri L, Määttä JA, Tvorogov D, Paatero I, Savisalo M, Silvennoinen O, Yarden Y, Elenius K. Differential nuclear localization and kinase activity of alternative ErbB4 intracellular domains. Oncogene. 26: 6905-14. PMID 17486069 DOI: 10.1038/Sj.Onc.1210501  0.487
2007 Shtiegman K, Kochupurakkal BS, Zwang Y, Pines G, Starr A, Vexler A, Citri A, Katz M, Lavi S, Ben-Basat Y, Benjamin S, Corso S, Gan J, Yosef RB, Giordano S, ... Yarden Y, et al. Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling. Oncogene. 26: 6968-78. PMID 17486068 DOI: 10.1038/Sj.Onc.1210503  0.842
2007 Ben-Yosef R, Starr A, Karaush V, Loew V, Lev-Ari S, Barnea I, Lidawi G, Shtabsky A, Greif Y, Yarden Y, Vexler A. ErbB-4 may control behavior of prostate cancer cells and serve as a target for molecular therapy. The Prostate. 67: 871-80. PMID 17440944 DOI: 10.1002/Pros.20555  0.345
2007 Amit I, Citri A, Shay T, Lu Y, Katz M, Zhang F, Tarcic G, Siwak D, Lahad J, Jacob-Hirsch J, Amariglio N, Vaisman N, Segal E, Rechavi G, Alon U, ... ... Yarden Y, et al. A module of negative feedback regulators defines growth factor signaling. Nature Genetics. 39: 503-12. PMID 17322878 DOI: 10.1038/Ng1987  0.736
2007 Bublil EM, Yarden Y. The EGF receptor family: spearheading a merger of signaling and therapeutics. Current Opinion in Cell Biology. 19: 124-34. PMID 17314037 DOI: 10.1016/J.Ceb.2007.02.008  0.528
2007 Katz M, Amit I, Yarden Y. Regulation of MAPKs by growth factors and receptor tyrosine kinases. Biochimica Et Biophysica Acta. 1773: 1161-76. PMID 17306385 DOI: 10.1016/J.Bbamcr.2007.01.002  0.564
2007 Spector N, Xia W, El-Hariry I, Yarden Y, Bacus S. HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors Breast Cancer Research. 9. DOI: 10.1186/bcr1652  0.406
2007 Zwang Y, Yarden Y. Growth factor signalling: ample opportunities for pharmaceutical interventions in oncology European Journal of Cancer, Supplement. 5: 427-429. DOI: 10.1016/S1359-6349(07)70086-1  0.734
2006 Zwang Y, Yarden Y. p38 MAP kinase mediates stress-induced internalization of EGFR: implications for cancer chemotherapy. The Embo Journal. 25: 4195-206. PMID 16932740 DOI: 10.1038/Sj.Emboj.7601297  0.807
2006 Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nature Reviews. Molecular Cell Biology. 7: 505-16. PMID 16829981 DOI: 10.1038/Nrm1962  0.703
2006 Katz M, Mosesson Y, Yarden Y. In vitro and in vivo assays of monoubiquitination of receptor tyrosine kinases. Methods in Molecular Biology (Clifton, N.J.). 327: 115-29. PMID 16780216 DOI: 10.1385/1-59745-012-X:115  0.586
2006 Germano S, Barberis D, Santoro MM, Penengo L, Citri A, Yarden Y, Gaudino G. Geldanamycins trigger a novel Ron degradative pathway, hampering oncogenic signaling. The Journal of Biological Chemistry. 281: 21710-9. PMID 16740632 DOI: 10.1074/Jbc.M602014200  0.785
2006 Oved S, Mosesson Y, Zwang Y, Santonico E, Shtiegman K, Marmor MD, Kochupurakkal BS, Katz M, Lavi S, Cesareni G, Yarden Y. Conjugation to Nedd8 instigates ubiquitylation and down-regulation of activated receptor tyrosine kinases. The Journal of Biological Chemistry. 281: 21640-51. PMID 16735510 DOI: 10.1074/Jbc.M513034200  0.837
2006 Mosesson Y, Yarden Y. Monoubiquitylation: a recurrent theme in membrane protein transport. The Israel Medical Association Journal : Imaj. 8: 233-7. PMID 16671356  0.351
2006 Li R, Soosairajah J, Harari D, Citri A, Price J, Ng HL, Morton CJ, Parker MW, Yarden Y, Bernard O. Hsp90 increases LIM kinase activity by promoting its homo-dimerization. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 20: 1218-20. PMID 16641196 DOI: 10.1096/Fj.05-5258Fje  0.731
2006 Citri A, Harari D, Shohat G, Ramakrishnan P, Gan J, Lavi S, Eisenstein M, Kimchi A, Wallach D, Pietrokovski S, Yarden Y. Hsp90 recognizes a common surface on client kinases. The Journal of Biological Chemistry. 281: 14361-9. PMID 16551624 DOI: 10.1074/Jbc.M512613200  0.729
2006 Starr A, Greif J, Vexler A, Ashkenazy-Voghera M, Gladesh V, Rubin C, Kerber G, Marmor S, Lev-Ari S, Inbar M, Yarden Y, Ben-Yosef R. ErbB4 increases the proliferation potential of human lung cancer cells and its blockage can be used as a target for anti-cancer therapy. International Journal of Cancer. Journal International Du Cancer. 119: 269-74. PMID 16463386 DOI: 10.1002/Ijc.21818  0.437
2006 Zsebik B, Citri A, Isola J, Yarden Y, Szöllosi J, Vereb G. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1. Immunology Letters. 104: 146-55. PMID 16384610 DOI: 10.1016/J.Imlet.2005.11.018  0.731
2005 Bacus S, Spector NL, Yarden Y. The era of ErbB-receptor-targeted therapies: advances toward personalized medicine. Personalized Medicine. 2: 301-315. PMID 29788579 DOI: 10.2217/17410541.2.4.301  0.378
2005 Sakaki Y, Kholodenko BN, Hatakeyama M, Kitano H, Kolch W, De Meyts P, Yarden Y, Westerhoff HV, Wiley HS. The International Consortium on Systems Biology of Receptor Tyrosine Kinase Regulatory Networks. Systems Biology. 152: 53-4. PMID 17044231 DOI: 10.1049/ip-syb:20059002  0.337
2005 Bacus SS, Gudkov AV, Esteva FJ, Yarden Y. Expression of erbB receptors and their ligands in breast cancer: implications to biological behavior and therapeutic response. Breast Disease. 11: 63-75. PMID 15687593 DOI: 10.3233/Bd-1999-11106  0.434
2005 Rubin C, Gur G, Yarden Y. Negative regulation of receptor tyrosine kinases: unexpected links to c-Cbl and receptor ubiquitylation. Cell Research. 15: 66-71. PMID 15686631 DOI: 10.1038/Sj.Cr.7290268  0.561
2005 Friedman LM, Rinon A, Schechter B, Lyass L, Lavi S, Bacus SS, Sela M, Yarden Y. Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: Implications for cancer immunotherapy Proceedings of the National Academy of Sciences of the United States of America. 102: 1915-1920. PMID 15684082 DOI: 10.1073/Pnas.0409610102  0.592
2005 Rubin C, Zwang Y, Vaisman N, Ron D, Yarden Y. Phosphorylation of carboxyl-terminal tyrosines modulates the specificity of Sprouty-2 inhibition of different signaling pathways. The Journal of Biological Chemistry. 280: 9735-44. PMID 15637081 DOI: 10.1074/Jbc.M408308200  0.812
2005 Kochupurakkal BS, Harari D, Di-Segni A, Maik-Rachline G, Lyass L, Gur G, Kerber G, Citri A, Lavi S, Eilam R, Chalifa-Caspi V, Eshhar Z, Pikarsky E, Pinkas-Kramarski R, Bacus SS, ... Yarden Y, et al. Epigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicity. The Journal of Biological Chemistry. 280: 8503-12. PMID 15611079 DOI: 10.1074/Jbc.M413919200  0.796
2005 Kario E, Marmor MD, Adamsky K, Citri A, Amit I, Amariglio N, Rechavi G, Yarden Y. Suppressors of cytokine signaling 4 and 5 regulate epidermal growth factor receptor signaling. The Journal of Biological Chemistry. 280: 7038-48. PMID 15590694 DOI: 10.1074/Jbc.M408575200  0.793
2004 Citri A, Gan J, Mosesson Y, Vereb G, Szollosi J, Yarden Y. Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation. Embo Reports. 5: 1165-70. PMID 15568014 DOI: 10.1038/Sj.Embor.7400300  0.788
2004 Yarden Y, Baselga J, Miles D. Molecular approach to breast cancer treatment. Seminars in Oncology. 31: 6-13. PMID 15490369 DOI: 10.1053/J.Seminoncol.2004.07.016  0.369
2004 Gur G, Rubin C, Katz M, Amit I, Citri A, Nilsson J, Amariglio N, Henriksson R, Rechavi G, Hedman H, Wides R, Yarden Y. LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. The Embo Journal. 23: 3270-81. PMID 15282549 DOI: 10.1038/Sj.Emboj.7600342  0.796
2004 Amit I, Yakir L, Katz M, Zwang Y, Marmor MD, Citri A, Shtiegman K, Alroy I, Tuvia S, Reiss Y, Roubini E, Cohen M, Wides R, Bacharach E, Schubert U, ... Yarden Y, et al. Tal, a Tsg101-specific E3 ubiquitin ligase, regulates receptor endocytosis and retrovirus budding. Genes & Development. 18: 1737-52. PMID 15256501 DOI: 10.1101/Gad.294904  0.831
2004 Mosesson Y, Yarden Y. Oncogenic growth factor receptors: implications for signal transduction therapy. Seminars in Cancer Biology. 14: 262-70. PMID 15219619 DOI: 10.1016/J.Semcancer.2004.04.005  0.58
2004 Marmor MD, Yarden Y. Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases. Oncogene. 23: 2057-70. PMID 15021893 DOI: 10.1038/Sj.Onc.1207390  0.598
2004 Marmor MD, Skaria KB, Yarden Y. Signal transduction and oncogenesis by ErbB/HER receptors. International Journal of Radiation Oncology, Biology, Physics. 58: 903-13. PMID 14967450 DOI: 10.1016/J.Ijrobp.2003.06.002  0.601
2004 Gur G, Yarden Y. Enlightened receptor dynamics. Nature Biotechnology. 22: 169-70. PMID 14755288 DOI: 10.1038/Nbt0204-169  0.378
2004 Kochupurakkal BS, Yarden Y. Signaling by growth factor receptors. Methods in Molecular Biology (Clifton, N.J.). 250: 177-202. PMID 14755089 DOI: 10.1385/1-59259-671-1:177  0.513
2004 Citri A, Kochupurakkal BS, Yarden Y. The achilles heel of ErbB-2/HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological intervention. Cell Cycle (Georgetown, Tex.). 3: 51-60. PMID 14657666 DOI: 10.4161/Cc.3.1.607  0.777
2003 Shelly M, Mosesson Y, Citri A, Lavi S, Zwang Y, Melamed-Book N, Aroeti B, Yarden Y. Polar expression of ErbB-2/HER2 in epithelia. Bimodal regulation by Lin-7. Developmental Cell. 5: 475-86. PMID 12967566 DOI: 10.1016/J.Devcel.2003.08.001  0.837
2003 Penengo L, Rubin C, Yarden Y, Gaudino G. c-Cbl is a critical modulator of the Ron tyrosine kinase receptor. Oncogene. 22: 3669-79. PMID 12802274 DOI: 10.1038/Sj.Onc.1206585  0.494
2003 Mosesson Y, Shtiegman K, Katz M, Zwang Y, Vereb G, Szollosi J, Yarden Y. Endocytosis of receptor tyrosine kinases is driven by monoubiquitylation, not polyubiquitylation. The Journal of Biological Chemistry. 278: 21323-6. PMID 12719435 DOI: 10.1074/Jbc.C300096200  0.836
2003 Citri A, Skaria KB, Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Experimental Cell Research. 284: 54-65. PMID 12648465 DOI: 10.1016/S0014-4827(02)00101-5  0.805
2003 Bao J, Gur G, Yarden Y. Src promotes destruction of c-Cbl: implications for oncogenic synergy between Src and growth factor receptors. Proceedings of the National Academy of Sciences of the United States of America. 100: 2438-43. PMID 12604776 DOI: 10.1073/Pnas.0437945100  0.544
2003 Rubin C, Litvak V, Medvedovsky H, Zwang Y, Lev S, Yarden Y. Sprouty fine-tunes EGF signaling through interlinked positive and negative feedback loops. Current Biology : Cb. 13: 297-307. PMID 12593795 DOI: 10.1016/S0960-9822(03)00053-8  0.849
2003 Shtiegman K, Yarden Y. The role of ubiquitylation in signaling by growth factors: implications to cancer. Seminars in Cancer Biology. 13: 29-40. PMID 12507554 DOI: 10.1016/S1044-579X(02)00097-4  0.572
2002 Huotari MA, Miettinen PJ, Palgi J, Koivisto T, Ustinov J, Harari D, Yarden Y, Otonkoski T. ErbB signaling regulates lineage determination of developing pancreatic islet cells in embryonic organ culture. Endocrinology. 143: 4437-46. PMID 12399441 DOI: 10.1210/En.2002-220382  0.464
2002 Katz M, Shtiegman K, Tal-Or P, Yakir L, Mosesson Y, Harari D, Machluf Y, Asao H, Jovin T, Sugamura K, Yarden Y. Ligand-independent degradation of epidermal growth factor receptor involves receptor ubiquitylation and Hgs, an adaptor whose ubiquitin-interacting motif targets ubiquitylation by Nedd4. Traffic (Copenhagen, Denmark). 3: 740-51. PMID 12230472 DOI: 10.1034/J.1600-0854.2002.31006.X  0.802
2002 Citri A, Alroy I, Lavi S, Rubin C, Xu W, Grammatikakis N, Patterson C, Neckers L, Fry DW, Yarden Y. Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy. The Embo Journal. 21: 2407-17. PMID 12006493 DOI: 10.1093/Emboj/21.10.2407  0.775
2002 Oved S, Yarden Y. Signal transduction: molecular ticket to enter cells. Nature. 416: 133-6. PMID 11894079 DOI: 10.1038/416133A  0.344
2002 Waterman H, Katz M, Rubin C, Shtiegman K, Lavi S, Elson A, Jovin T, Yarden Y. A mutant EGF-receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling. The Embo Journal. 21: 303-13. PMID 11823423 DOI: 10.1093/Emboj/21.3.303  0.571
2002 Yarden Y. Overview of HER2 and Type I growth factor receptor influences in breast cancer development and biology European Journal of Cancer. 38: S48. DOI: 10.1016/S0959-8049(02)80123-X  0.435
2001 Yarden Y. Biology of HER2 and its importance in breast cancer Oncology. 61: 1-13. PMID 11694782 DOI: 10.1159/000055396  0.567
2001 Yarden Y. The EGFR family and its ligands in human cancer: Signalling mechanisms and therapeutic opportunities European Journal of Cancer. 37. PMID 11597398 DOI: 10.1016/S0959-8049(01)00230-1  0.592
2001 Rubin I, Yarden Y. The basic biology of HER2. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 12: S3-8. PMID 11521719 DOI: 10.1093/Annonc/12.Suppl_1.S3  0.569
2001 Ettenberg SA, Magnifico A, Cuello M, Nau MM, Rubinstein YR, Yarden Y, Weissman AM, Lipkowitz S. Cbl-b-dependent Coordinated Degradation of the Epidermal Growth Factor Receptor Signaling Complex Journal of Biological Chemistry. 276: 27677-27684. PMID 11375397 DOI: 10.1074/Jbc.M102641200  0.505
2001 Bacus SS, Gudkov AV, Lowe M, Lyass L, Yung Y, Komarov AP, Keyomarsi K, Yarden Y, Seger R. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene. 20: 147-55. PMID 11313944 DOI: 10.1038/Sj.Onc.1204062  0.353
2001 Waterman H, Yarden Y. Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases Febs Letters. 490: 142-152. PMID 11223029 DOI: 10.1016/S0014-5793(01)02117-2  0.569
2001 Xu W, Mimnaugh E, Rosser MF, Nicchitta C, Marcu M, Yarden Y, Neckers L. Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. The Journal of Biological Chemistry. 276: 3702-8. PMID 11071886 DOI: 10.1074/Jbc.M006864200  0.424
2001 Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network Nature Reviews Molecular Cell Biology. 2: 127-137. DOI: 10.1038/35052073  0.447
2000 Vaisman N, Nissim A, Klapper LN, Tirosh B, Yarden Y, Sela M. Specific inhibition of the reaction between a tumor-inhibitory antibody and the ErbB-2 receptor by a mimotope derived from a phage display library. Immunology Letters. 75: 61-7. PMID 11163868 DOI: 10.1016/S0165-2478(00)00278-9  0.408
2000 Harari D, Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer Oncogene. 19: 6102-6114. PMID 11156523 DOI: 10.1038/Sj.Onc.1203973  0.558
2000 Hurwitz E, Klapper LN, Wilchek M, Yarden Y, Sela M. Inhibition of tumor growth by poly(ethylene glycol) derivatives of anti-ErbB2 antibodies. Cancer Immunology, Immunotherapy : Cii. 49: 226-34. PMID 10941905 DOI: 10.1007/S002620000112  0.336
2000 Levkowitz G, Oved S, Klapper LN, Harari D, Lavi S, Sela M, Yarden Y. c-Cbl is a suppressor of the neu oncogene. The Journal of Biological Chemistry. 275: 35532-9. PMID 10940298 DOI: 10.1074/Jbc.M002661200  0.751
2000 Klapper LN, Waterman H, Sela M, Yarden Y. Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Research. 60: 3384-8. PMID 10910043  0.352
2000 Zhu Z, Kleeff J, Friess H, Wang L, Zimmermann A, Yarden Y, Büchler MW, Korc M. Epiregulin is Up-regulated in pancreatic cancer and stimulates pancreatic cancer cell growth. Biochemical and Biophysical Research Communications. 273: 1019-24. PMID 10891365 DOI: 10.1006/Bbrc.2000.3033  0.38
2000 Bao J, Alroy I, Waterman H, Schejter ED, Brodie C, Gruenberg J, Yarden Y. Threonine phosphorylation diverts internalized epidermal growth factor receptors from a degradative pathway to the recycling endosome Journal of Biological Chemistry. 275: 26178-26186. PMID 10816576 DOI: 10.1074/Jbc.M002367200  0.589
2000 Kirschbaum MH, Yarden Y. The ErbB/HER family of receptor tyrosine kinases: A potential target for chemoprevention of epithelial neoplasms Journal of Cellular Biochemistry. 77: 52-60. PMID 10762015 DOI: 10.1002/(Sici)1097-4644(2000)77:34+<52::Aid-Jcb10>3.0.Co;2-X  0.566
2000 Chausovsky A, Waterman H, Elbaum M, Yarden Y, Geiger B, Bershadsky AD. Molecular requirements for the effect of neuregulin on cell spreading, motility and colony organization. Oncogene. 19: 878-88. PMID 10702796 DOI: 10.1038/Sj.Onc.1203410  0.545
2000 Lee RJ, Albanese C, Fu M, D'Amico M, Lin B, Watanabe G, Haines GK, Siegel PM, Hung MC, Yarden Y, Horowitz JM, Muller WJ, Pestell RG. Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Molecular and Cellular Biology. 20: 672-83. PMID 10611246 DOI: 10.1128/Mcb.20.2.672-683.2000  0.435
2000 Klapper LN, Kirschbaum MH, Sela M, Yarden Y. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors Advances in Cancer Research. 77: 25-79. PMID 10549355  0.515
2000 Alroy I, Yarden Y. Biochemistry of HER2 oncogenesis in breast cancer Breast Disease. 11: 31-48. DOI: 10.3233/Bd-1999-11104  0.591
2000 Bacus SS, Gudkov AV, Esteva FJ, Yarden Y. Expression of erbB receptors and their ligands in breast cancer: Implications to biological behavior and therapeutic response Breast Disease. 11: 63-75.  0.322
1999 Levkowitz G, Waterman H, Ettenberg SA, Katz M, Tsygankov AY, Alroy I, Lavi S, Iwai K, Reiss Y, Ciechanover A, Lipkowitz S, Yarden Y. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1 Molecular Cell. 4: 1029-1040. PMID 10635327 DOI: 10.1016/S1097-2765(00)80231-2  0.798
1999 Waterman H, Levkowitz G, Alroy I, Yarden Y. The RING finger of c-Cbl mediates desensitization of the epidermal growth factor receptor. The Journal of Biological Chemistry. 274: 22151-4. PMID 10428778 DOI: 10.1074/Jbc.274.32.22151  0.792
1999 Waterman H, Alroy I, Strano S, Seger R, Yarden Y. The C-terminus of the kinase-defective neuregulin receptor ErbB-3 confers mitogenic superiority and dictates endocytic routing Embo Journal. 18: 3348-3358. PMID 10369675 DOI: 10.1093/Emboj/18.12.3348  0.593
1999 Brizzi MF, Dentelli P, Rosso A, Yarden Y, Pegoraro L. STAT protein recruitment and activation in c-Kit deletion mutants Journal of Biological Chemistry. 274: 16965-16972. PMID 10358045 DOI: 10.1074/Jbc.274.24.16965  0.489
1999 Harari D, Tzahar E, Romano J, Shelly M, Pierce JH, Andrews GC, Yarden Y. Neuregulin-4: A novel growth factor that acts through the ErbB-4 receptor tyrosine kinase Oncogene. 18: 2681-2689. PMID 10348342 DOI: 10.1038/Sj.Onc.1202631  0.591
1999 Klapper LN, Glathe S, Vaisman N, Hynes NE, Andrews GC, Sela M, Yarden Y. The erbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors Proceedings of the National Academy of Sciences of the United States of America. 96: 4995-5000. PMID 10220407 DOI: 10.1073/Pnas.96.9.4995  0.561
1999 Alroy I, Soussan L, Seger R, Yarden Y. Neu differentiation factor stimulates phosphorylation and activation of the Sp1 transcription factor Molecular and Cellular Biology. 19: 1961-1972. PMID 10022883 DOI: 10.1128/Mcb.19.3.1961  0.528
1999 Pinkas-Kramarski R, Shelly M, Guarino BC, Wang LM, Lyass L, Alroy I, Alimandi M, Kuo A, Moyer JD, Lavi S, Eisenstein M, Ratzkin BJ, Seger R, Bacus SS, Pierce JH, ... ... Yarden Y, et al. ErbB Tyrosine Kinases and the Two Neuregulin Families Constitute a Ligand-Receptor Network Molecular and Cellular Biology. 19: 8695-8695. DOI: 10.1128/mcb.19.12.8695  0.367
1999 Yarden Y. HER2/neu oncoprotein of human adenocarcinomas: an amplifier of signal transduction by stromal growth factor European Journal of Cancer. 35: S133. DOI: 10.1016/S0959-8049(99)80915-0  0.428
1998 Levkowitz G, Waterman H, Zamir E, Kam Z, Oved S, Langdon WY, Beguinot L, Geiger B, Yarden Y. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes & Development. 12: 3663-74. PMID 9851973 DOI: 10.1101/Gad.12.23.3663  0.808
1998 Chausovsky A, Tsarfaty I, Kam Z, Yarden Y, Geiger B, Bershadsky AD. Morphogenetic effects of neuregulin (neu differentiation factor) in cultured epithelial cells. Molecular Biology of the Cell. 9: 3195-209. PMID 9802906 DOI: 10.1091/Mbc.9.11.3195  0.48
1998 Tzahar E, Moyer JD, Waterman H, Barbacci EG, Bao J, Levkowitz G, Shelly M, Strano S, Pinkas-Kramarski R, Pierce JH, Andrews GC, Yarden Y. Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network. The Embo Journal. 17: 5948-63. PMID 9774339 DOI: 10.1093/Emboj/17.20.5948  0.786
1998 Pinkas-Kramarski R, Shelly M, Guarino BC, Wang LM, Lyass L, Alroy I, Alamandi M, Kuo A, Moyer JD, Lavi S, Eisenstein M, Ratzkin BJ, Seger R, Bacus SS, Pierce JH, ... ... Yarden Y, et al. ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network Molecular and Cellular Biology. 18: 6090-6101. PMID 9742126 DOI: 10.1128/Mcb.18.10.6090  0.554
1998 Lenferink AEG, Pinkas-Kramarski R, Van De Poll MLM, Van Vugt MJH, Klapper LN, Tzahar E, Waterman H, Sela M, Van Zoelen EJJ, Yarden Y. Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers Embo Journal. 17: 3385-3397. PMID 9628875 DOI: 10.1093/Emboj/17.12.3385  0.602
1998 Waterman H, Sabanai I, Geiger B, Yarden Y. Alternative intracellular routing of ErbB receptors may determine signaling potency Journal of Biological Chemistry. 273: 13819-13827. PMID 9593726 DOI: 10.1074/Jbc.273.22.13819  0.547
1998 Shelly M, Pinkas-Kramarski R, Guarino BC, Waterman H, Wang LM, Lyass L, Alimandi M, Kuo A, Bacus SS, Pierce JH, Andrews GC, Yarden Y. Epiregulin is a potent Pan-ErbB ligand that preferentially activates heterodimeric receptor complexes Journal of Biological Chemistry. 273: 10496-10505. PMID 9553109 DOI: 10.1074/Jbc.273.17.10496  0.579
1998 Pinkas-Kramarski R, Lenferink AEG, Bacus SS, Lyass L, Van De Poll MLM, Klapper LN, Tzahar E, Sela M, Van Zoelen EJJ, Yarden Y. The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin Oncogene. 16: 1249-1258. PMID 9546426 DOI: 10.1038/Sj.Onc.1201642  0.598
1998 Tzahar E, Yarden Y. The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: From orphanhood to multiple stromal ligands Biochimica Et Biophysica Acta - Reviews On Cancer. 1377. PMID 9540810 DOI: 10.1016/S0304-419X(97)00032-2  0.594
1998 Eilam R, Pinkas-Kramarski R, Ratzkin BJ, Segal M, Yarden Y. Activity-dependent regulation of Neu differentiation factor/neuregulin expression in rat brain Proceedings of the National Academy of Sciences of the United States of America. 95: 1888-1893. PMID 9465112 DOI: 10.1073/Pnas.95.4.1888  0.443
1998 Zrihan-Licht S, Deng B, Yarden Y, McShan G, Keydar I, Avraham H. Csk homologous kinase, a novel signaling molecule, directly associates with the activated ErbB-2 receptor in breast cancer cells and inhibits their proliferation Journal of Biological Chemistry. 273: 4065-4072. PMID 9461599 DOI: 10.1074/Jbc.273.7.4065  0.511
1998 Pinkas-Kramarski R, Shelly M, Guarino BC, Wang LM, Lyass L, Alroy I, Alimandi M, Kuo A, Moyer JD, Lavi S, Eisenstein M, Ratzkin BJ, Seger R, Bacus SS, Pierce JH, ... ... Yarden Y, et al. ErbB Tyrosine Kinases and the Two Neuregulin Families Constitute a Ligand-Receptor Network Molecular and Cellular Biology. 18: 7602-7602. DOI: 10.1128/MCB.18.12.7602  0.367
1998 Bacus S, Yarden Y, Kaminsky D. Neu differentiation factor (NDF/heregulin) induces expression of adhesion molecules, increased cellular invasiveness, and is expressed in Paget's disease of the breast together with its receptors European Journal of Cancer. 34: S116. DOI: 10.1016/S0959-8049(98)80486-3  0.375
1997 Pinkas-Kramarski R, Alroy I, Yarden Y. ErbB receptors and EGF-like ligands: Cell lineage determination and oncogenesis through combinatorial signaling Journal of Mammary Gland Biology and Neoplasia. 2: 97-107. PMID 10882296 DOI: 10.1023/A:1026343528967  0.569
1997 Pinkas-Kramarski R, Eilam R, Alroy I, Levkowitz G, Lonai P, Yarden Y. Differential expression of NDF/neuregulin receptors ErbB-3 and ErbB-4 and involvement in inhibition of neuronal differentiation. Oncogene. 15: 2803-15. PMID 9419971 DOI: 10.1038/Sj.Onc.1201466  0.74
1997 Tzahar E, Pinkas-Kramarski R, Moyer JD, Klapper LN, Alroy I, Levkowitz G, Shelly M, Henis S, Eisenstein M, Ratzkin BJ, Sela M, Andrews GC, Yarden Y. Bivalence of EGF-like ligands drives the ErbB signaling network. The Embo Journal. 16: 4938-50. PMID 9305636 DOI: 10.1093/Emboj/16.16.4938  0.775
1997 Alroy I, Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: Signal diversification through combinatorial ligand-receptor interactions Febs Letters. 410: 83-86. PMID 9247128 DOI: 10.1016/S0014-5793(97)00412-2  0.557
1997 Burden S, Yarden Y. Neuregulins and their receptors: A versatile signaling module in organogenesis and oncogenesis Neuron. 18: 847-855. PMID 9208852 DOI: 10.1016/S0896-6273(00)80324-4  0.403
1997 Klapper LN, Vaisman N, Hurwitz E, Pinkas-Kramarski R, Yarden Y, Sela M. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors Oncogene. 14: 2099-2109. PMID 9160890 DOI: 10.1038/Sj.Onc.1201029  0.552
1997 Yarden Y. Growth factors and ErbB/HER tyrosine kinases: How do they contribute to malignancy? European Journal of Cancer. 33: S223-S224. DOI: 10.1016/S0959-8049(97)85780-2  0.465
1996 Goren D, Horowitz AT, Zalipsky S, Woodle MC, Yarden Y, Gabizon A. Targeting of stealth liposomes to erbB-2 (Her/2) receptor: In vitro and in vivo studies British Journal of Cancer. 74: 1749-1756. PMID 8956788 DOI: 10.1038/Bjc.1996.625  0.338
1996 Kristt DA, Yarden Y. Differences between phosphotyrosine accumulation and Neu/ErbB-2 receptor expression in astrocytic proliferative processes: Implications for glial oncogenesis Cancer. 78: 1272-1283. PMID 8826951 DOI: 10.1002/(Sici)1097-0142(19960915)78:6<1272::Aid-Cncr16>3.0.Co;2-Y  0.526
1996 Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ, Yarden Y. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Molecular and Cellular Biology. 16: 5276-87. PMID 8816440 DOI: 10.1128/Mcb.16.10.5276  0.802
1996 Mincione G, Bianco C, Kannan S, Colletta G, Ciardiello F, Sliwkowski M, Yarden Y, Normanno N, Pramaggiore A, Kim N, Salomon DS. Enhanced Expression Of Heregulin In C-Erb B-2 And C-Ha-Ras Transformed Mouse And Human Mammary Epithelial Cells Journal of Cellular Biochemistry. 60: 437-446. PMID 8707884 DOI: 10.1002/(Sici)1097-4644(19960315)60:4<437::Aid-Jcb1>3.0.Co;2-T  0.337
1996 Pinkas-Kramarski R, Shelly M, Glathe S, Ratzkin BJ, Yarden Y. Neu differentiation factor/neuregulin isoforms activate distinct receptor combinations Journal of Biological Chemistry. 271: 19029-19032. PMID 8702572 DOI: 10.1074/Jbc.271.32.19029  0.542
1996 Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin BJ, Sela M, Yarden Y. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. The Embo Journal. 15: 2452-67. PMID 8665853 DOI: 10.1002/J.1460-2075.1996.Tb00603.X  0.813
1996 Levkowitz G, Klapper LN, Tzahar E, Freywald A, Sela M, Yarden Y. Coupling of the c-Cbl protooncogene product to ErbB-1/EGF-receptor but not to other ErbB proteins. Oncogene. 12: 1117-25. PMID 8649804  0.771
1996 Brizzi MF, Aronica MG, Rosso A, Bagnara GP, Yarden Y, Pegoraro L. Granulocyte-macrophage colony-stimulating factor stimulates JAK2 signaling pathway and rapidly activates p93fes, STAT1 p91, and STAT3 p92 in polymorphonuclear leukocytes Journal of Biological Chemistry. 271: 3562-3567. PMID 8631962 DOI: 10.1074/Jbc.271.7.3562  0.457
1996 Chen X, Levkowitz G, Tzahar E, Karunagaran D, Lavi S, Ben-Baruch N, Leitner O, Ratzkin BJ, Bacus SS, Yarden Y. An immunological approach reveals biological differences between the two NDF/heregulin receptors, ErbB-3 and ErbB-4. The Journal of Biological Chemistry. 271: 7620-9. PMID 8631797 DOI: 10.1074/Jbc.271.13.7620  0.811
1996 Bacus SS, Chin D, Yarden Y, Zelnick CR, Stern DF. Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors American Journal of Pathology. 148: 549-558. PMID 8579117  0.489
1996 Beerli RR, Graus-Porta D, Woods-Cook K, Chen X, Yarden Y, Hynes NE. Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2. Molecular and Cellular Biology. 15: 6496-505. PMID 8524214 DOI: 10.1128/Mcb.15.12.6496  0.514
1996 Karunagaran D, Tzahar E, Beerli RR, Chen X, Graus-Porta D, Ratzkin BJ, Seger R, Hynes NE, Yarden Y. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. The Embo Journal. 15: 254-264. DOI: 10.1002/J.1460-2075.1996.Tb00356.X  0.598
1995 Lu HS, Chang D, Philo JS, Zhang K, Narhi LO, Liu N, Zhang M, Sun J, Wen J, Yanagihara D, Karunagaran D, Yarden Y, Ratzkin B. Studies on the structure and function of glycosylated and nonglycosylated neu differentiation factors. Similarities and differences of the alpha and beta isoforms. Journal of Biological Chemistry. 270: 4784-4791. PMID 7876251 DOI: 10.1074/Jbc.270.9.4784  0.336
1995 Marte BM, Jeschke M, Graus-Porta D, Taverna D, Hofer P, Groner B, Yarden Y, Hynes NE. Neu differentiation factor/heregulin modulates growth and differentiation of HC11 mammary epithelial cells. Molecular Endocrinology (Baltimore, Md.). 9: 14-23. PMID 7760847 DOI: 10.1210/Mend.9.1.7760847  0.452
1995 Karunagaran D, Tzahar E, Liu N, Wen D, Yarden Y. Neu differentiation factor inhibits EGF binding: A model for trans-regulation within the ErbB family of receptor tyrosine kinases Journal of Biological Chemistry. 270: 9982-9990. PMID 7730382 DOI: 10.1074/Jbc.270.17.9982  0.59
1995 Hurwitz E, Stancovski I, Sela M, Yarden Y. Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake Proceedings of the National Academy of Sciences of the United States of America. 92: 3353-3357. PMID 7724565 DOI: 10.1073/Pnas.92.8.3353  0.375
1995 Gilboa L, Ben-Levy R, Yarden Y, Henis YI. Roles for a cytoplasmic tyrosine and tyrosine kinase activity in the interactions of Neu receptors with coated pits Journal of Biological Chemistry. 270: 7061-7067. PMID 7706244 DOI: 10.1074/Jbc.270.13.7061  0.557
1995 Dong Z, Brennan A, Liu N, Yarden Y, Lefkowitz G, Mirsky R, Jessen KR. Neu differentiation factor is a neuron-glia signal and regulates survival, proliferation, and maturation of rat Schwann cell precursors. Neuron. 15: 585-96. PMID 7546738 DOI: 10.1016/0896-6273(95)90147-7  0.421
1995 Migdal M, Soker S, Yarden Y, Neufeld G. Activation of a transfected FGFR-1 receptor in Madin-Darby epithelial cells results in a reversible loss of epithelial properties Journal of Cellular Physiology. 162: 266-276. PMID 7529769 DOI: 10.1002/Jcp.1041620212  0.452
1995 Blechman JM, Lev S, Barg J, Eisenstein M, Vaks B, Vogel Z, Givol D, Yarden Y.. The fourth immunoglobulin domain of the stem cell factor receptor couples ligand binding to signal transduction. Cell. 80: 103-113. PMID 7529140 DOI: 10.1016/0092-8674(95)90455-7  0.845
1995 Blechman JM, Yarden Y. Structural aspects of receptor dimerization. c-Kit as an example Annals of the New York Academy of Sciences. 766: 344-362. PMID 7486681 DOI: 10.1111/J.1749-6632.1995.Tb26685.X  0.402
1994 Stancovski I, Sela M, Yarden Y. Molecular and clinical aspects of the Neu/ErbB-2 receptor tyrosine kinase Cancer Treatment and Research. 71: 161-191. PMID 7946947 DOI: 10.1007/978-1-4615-2592-9_9  0.544
1994 Bacus SS, Zelnick CR, Plowman G, Yarden Y. Expression of the erbB-2 family of growth factor receptors and their ligands in breast cancers: Implication for tumor biology and clinical behavior American Journal of Clinical Pathology. 102. PMID 7942609  0.464
1994 Ben-Levy R, Paterson HF, Marshall CJ, Yarden Y. A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway Embo Journal. 13: 3302-3311. PMID 7913890 DOI: 10.1002/J.1460-2075.1994.Tb06632.X  0.458
1994 Ben-Baruch N, Yarden Y. Neu Differentiation Factors: A Family of Alternatively Spliced Neuronal and Mesenchymal Factors Proceedings of the Society For Experimental Biology and Medicine. 206: 221-227. PMID 7912439 DOI: 10.3181/00379727-206-43746  0.534
1994 Lev S, Blechman JM, Givol D, Yarden Y. Steel factor and c-kit protooncogene: Genetic lessons in signal transduction Critical Reviews in Oncogenesis. 5: 141-168. PMID 7531500 DOI: 10.1615/Critrevoncog.V5.I2-3.30  0.832
1994 Lev S, Blechman JM, Givol D, Yarden Y.. Steel factor and c-kit protooncogene: genetic lessons in signal transduction. Crit Rev Oncog.. 5: 141-68. PMID 7531500 DOI: 10.1615/critrevoncog.v5.i2-3.30  0.86
1994 Brizzi MF, Zini MG, Aronica MG, Blechman JM, Yarden Y, Pegoraro L. Convergence of signaling by interleukin-3, granulocyte-macrophage colony- stimulating factor, and mast cell growth factor on JAK2 tyrosine kinase Journal of Biological Chemistry. 269: 31680-31684. PMID 7527392  0.463
1994 Brizzi MF, Blechman JM, Cavalloni G, Givol D, Yarden Y, Pegoraro L. Protein kinase C-dependent release of a functional whole extracellular domain of the mast cell growth factor (MGF) receptor by MGF-dependent human myeloid cells Oncogene. 9: 1583-1589. PMID 7514283  0.395
1993 Normanno N, Qi CF, Gullick WJ, Persico G, Yarden Y, Wen D, Plowman G, Kenney N, Johnson G, Kim N, Brandt R, Martinez-Lacaci I, Dickson RB, Salomon DS. Expression of amphiregulin, cripto-1, and heregulin-alpha in human breast-cancer cells. International Journal of Oncology. 2: 903-911. PMID 21573645 DOI: 10.3892/Ijo.2.6.903  0.342
1993 Kelman Z, Simon-Chazottes D, Guénet JL, Yarden Y. The murine vik gene (chromosome 9) encodes a putative receptor with unique protein kinase motifs Oncogene. 8: 37-44. PMID 8380921  0.368
1993 Peles E, Ben-Levy R, Tzahar E, Liu N, Wen D, Yarden Y. Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2 suggests complex ligand-receptor relationships. The Embo Journal. 12: 961-71. PMID 8096177 DOI: 10.1002/J.1460-2075.1993.Tb05737.X  0.791
1993 Orr-Urtreger A, Trakhtenbrot L, Ben-Levy R, Wen D, Rechavi G, Lonai P, Yarden Y. Neural expression and chromosomal mapping of Neu differentiation factor to 8p12-p21. Proceedings of the National Academy of Sciences of the United States of America. 90: 1867-71. PMID 8095334 DOI: 10.1073/Pnas.90.5.1867  0.369
1993 Peles E, Yarden Y. Neu and its ligands: from an oncogene to neural factors. Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology. 15: 815-24. PMID 7908191 DOI: 10.1002/Bies.950151207  0.812
1993 Stancovski I, Schindler DG, Waks T, Yarden Y, Sela M, Eshhar Z. Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. Journal of Immunology (Baltimore, Md. : 1950). 151: 6577-82. PMID 7902379  0.399
1993 Blechman JM, Lev S, Givol D, Yarden Y. Structure-function analyses of the Kit receptor for the steel factor Stem Cells. 11: 12-21. PMID 7691317 DOI: 10.1002/Stem.5530110804  0.808
1993 Blechman JM, Lev S, Givol D, Yarden Y.. Structure-function analyses of the kit receptor for the steel factor. Stem Cells.. 12-21. PMID 7691317 DOI: 10.1002/stem.5530110804  0.842
1993 Kristt DA, Reedy E, Yarden Y. Receptor tyrosine kinase expression in astrocytic lesions: Similar features in gliosis and glioma Neurosurgery. 33: 106-115. PMID 7689190 DOI: 10.1227/00006123-199307000-00017  0.461
1993 Zakut R, Perlis R, Eliyahu S, Yarden Y, Givol D, Lyman SD, Halaban R. KIT ligand (mast cell growth factor) inhibits the growth of KIT-expressing melanoma cells Oncogene. 8: 2221-2229. PMID 7687762  0.344
1993 Lev S, Blechman J, Nishikawa SI, Givol D, Yarden Y. Interspecies molecular chimeras of kit help define the binding site of the stem cell factor Molecular and Cellular Biology. 13: 2224-2234. PMID 7681144 DOI: 10.1128/Mcb.13.4.2224  0.459
1993 Lev S, Blechman J, Nishikawa S, Givol D, Yarden Y.. Interspecies molecular chimeras of kit help define the binding site of the stem cell factor. Mol Cell Biol.. 13: 2224-34.. PMID 7681144 DOI: 10.1128/mcb.13.4.2224  0.82
1993 Blechman JM, Lev S, Brizzi MF, Leitner O, Pegoraro L, Givol D, Yarden Y. Soluble c-Kit proteins and antireceptor monoclonal antibodies confine the binding site of the stem cell factor Journal of Biological Chemistry. 268: 4399-4406. PMID 7680037  0.366
1993 Kristt DA, Reedy E, Yarden Y. Receptor Tyrosine Kinase Expression in Astrocytic Lesions Neurosurgery. 33: 106-115. DOI: 10.1097/00006123-199307000-00017  0.435
1992 Lev S, Yarden Y, Givol D. Dimerization and activation of the kit receptor by monovalent and bivalent binding of the stem cell factor Journal of Biological Chemistry. 267: 15970-15977. PMID 1379243  0.816
1992 Lev S, Yarden Y, Givol D. A recombinant ectodomain of the receptor for the Stem Cell Factor (SCF) retains ligand-induced receptor dimerization and antagonizes SCF-stimulated cellular responses Journal of Biological Chemistry. 267: 10866-10873. PMID 1375232  0.815
1992 Bacus SS, Stancovski l, Hurwitz E, Mills GB, Ullrich A, Chin D, Huberman E, Sela M, Yarden Y. Tumor-inhibitory Monoclonal Antibodies to the HER-2/Neu Receptor Induce Differentiation of Human Breast Cancer Cells Cancer Research. 52: 2580-2589. PMID 1373672  0.331
1992 Funasaka Y, Boulton T, Cobb M, Yarden Y, Fan B, Lyman SD, Williams DE, Anderson DM, Zakut R, Mishima Y. c-Kit-kinase induces a cascade of protein tyrosine phosphorylation in normal human melanocytes in response to mast cell growth factor and stimulates mitogen-activated protein kinase but is down-regulated in melanomas. Molecular Biology of the Cell. 3: 197-209. PMID 1372524 DOI: 10.1091/Mbc.3.2.197  0.517
1992 Lev S, Givol D, Yarden Y. Interkinase domain of kit contains the binding site for phosphatidylinositol 3' kinase Proceedings of the National Academy of Sciences of the United States of America. 89: 678-682. PMID 1370584 DOI: 10.1073/Pnas.89.2.678  0.813
1992 Lev S, Givol D, Yarden Y.. Interkinase domain of kit contains the binding site for phosphatidylinositol 3' kinase. Proc Natl Acad Sci U S a.. 89: 678-82. PMID 1370584 DOI: 10.1073/pnas.89.2.678  0.846
1992 Stancovski I, Peles E, Ben Levy R, Lemprecht R, Kelman Z, Goldman-Michael R, Hurwitz E, Bacus S, Sela M, Yarden Y. Signal transduction by the neu/erbB-2 receptor: a potential target for anti-tumor therapy. The Journal of Steroid Biochemistry and Molecular Biology. 43: 95-103. PMID 1356018 DOI: 10.1016/0960-0760(92)90192-L  0.802
1992 Ben-Levy R, Peles E, Goldman-Michael R, Yarden Y. An oncogenic point mutation confers high affinity ligand binding to the neu receptor. Implications for the generation of site heterogeneity. The Journal of Biological Chemistry. 267: 17304-13. PMID 1355090  0.761
1992 Peles E, Lamprecht R, Ben-Levy R, Tzahar E, Yarden Y. Regulated coupling of the Neu receptor to phosphatidylinositol 3'-kinase and its release by oncogenic activation. The Journal of Biological Chemistry. 267: 12266-74. PMID 1351056  0.758
1992 Wen D, Peles E, Cupples R, Suggs SV, Bacus SS, Luo Y, Trail G, Hu S, Silbiger SM, Levy RB, Koski RA, Lu HS, Yarden Y. Neu differentiation factor: A transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit Cell. 69: 559-572. PMID 1349853 DOI: 10.1016/0092-8674(92)90456-M  0.749
1992 Peles E, Bacus SS, Koski RA, Lu HS, Wen D, Ogden SG, Levy RB, Yarden Y. Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell. 69: 205-16. PMID 1348215 DOI: 10.1016/0092-8674(92)90131-U  0.757
1992 Yayon A, Zimmer Y, Shen GH, Avivi A, Yarden Y, Givol D. A confined variable region confers ligand specificity on fibroblast growth factor receptors: implications for the origin of the immunoglobulin fold. The Embo Journal. 11: 1885-90. PMID 1316275 DOI: 10.1002/J.1460-2075.1992.Tb05240.X  0.546
1992 Hemmerich S, Yarden Y, Pecht I. A cromoglycate binding protein from rat mast cells of a leukemia line is a nucleoside diphosphate kinase Biochemistry. 31: 4574-4579. PMID 1316151 DOI: 10.1021/Bi00134A006  0.417
1992 Yarden Y. Cell activation: Genetic approaches. Advances in regulation of cell growth. Vol. 2 Molecular Immunology. 29: 697-698. DOI: 10.1016/0161-5890(92)90207-E  0.34
1992 Avivi A, Zimmer Y, Yayon A, Yarden Y, Givol D. Corrigendum: Flg-2, a new member of the family of fibroblast growth factor receptors (Oncogene (1991) 6 (1089-1092)) Oncogene. 7: 823.  0.328
1991 Stancovski I, Hurwitz E, Leitner O, Ullrich A, Yarden Y, Sela M. Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth Proceedings of the National Academy of Sciences of the United States of America. 88: 8691-8695. PMID 1717984 DOI: 10.1073/Pnas.88.19.8691  0.475
1991 Raz V, Kelman Z, Avivi A, Neufeld G, Givol D, Yarden Y. PCR-based identification of new receptors: Molecular cloning of a receptor for fibroblast growth factors Oncogene. 6: 753-760. PMID 1711190  0.496
1991 Lev S, Givol D, Yarden Y. A specific combination of substrates is involved in signal transduction by the kit-encoded receptor Embo Journal. 10: 647-654. PMID 1705885 DOI: 10.1002/J.1460-2075.1991.Tb07993.X  0.86
1991 Kashles O, Yarden Y, Fischer R, Ullrich A, Schlessinger J. A dominant negative mutation suppresses the function of normal epidermal growth factor receptors by heterodimerization. Molecular and Cellular Biology. 11: 1454-63. PMID 1705006 DOI: 10.1128/Mcb.11.3.1454  0.726
1991 Peles E, Levy RB, Or E, Ullrich A, Yarden Y. Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma. The Embo Journal. 10: 2077-86. PMID 1676673 DOI: 10.1002/J.1460-2075.1991.Tb07739.X  0.798
1991 Yarden Y, Peles E. Biochemical analysis of the ligand for the neu oncogenic receptor. Biochemistry. 30: 3543-50. PMID 1672825 DOI: 10.1021/Bi00228A027  0.788
1991 Orr-Urtreger A, Givol D, Yayon A, Yarden Y, Lonai P. Developmental expression of two murine fibroblast growth factor receptors, flg and bek Development. 113: 1419-1434. PMID 1667382  0.353
1991 Avivi A, Zimmer Y, Yayon A, Yarden Y, Givol D. Flg-2, a new member of the family of fibroblast growth factor receptors Oncogene. 6: 1089-1092. PMID 1648703  0.368
1991 Yarden Y, Kelman Z. Transmembrane signalling receptors for cytokines and growth factors Current Opinion in Structural Biology. 1: 582-589. DOI: 10.1016/S0959-440X(05)80081-8  0.546
1990 Yarden Y. Receptor-like oncogenes: Functional analysis through novel experimental approaches Molecular Immunology. 27: 1319-1324. PMID 1980338 DOI: 10.1016/0161-5890(90)90037-Z  0.516
1990 Goldman R, Levy RB, Peles E, Yarden Y. Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. Biochemistry. 29: 11024-8. PMID 1980216 DOI: 10.1021/Bi00502A002  0.8
1990 Yarden Y. Agonistic antibodies stimulate the kinase encoded by the neu protooncogene in living cells but the oncogenic mutant is constitutively active Proceedings of the National Academy of Sciences of the United States of America. 87: 2569-2573. PMID 1969636 DOI: 10.1073/Pnas.87.7.2569  0.521
1990 Lev S, Yarden Y, Givol D. Receptor functions and ligand-dependent transforming potential of a chimeric kit proto-oncogene Molecular and Cellular Biology. 10: 6064-6068. PMID 1700279 DOI: 10.1128/Mcb.10.11.6064  0.835
1990 Lev S, Yarden Y, Givol D.. Receptor functions and ligand-dependent transforming potential of a chimeric kit proto-oncogene. Mol Cell Biol.. 10: 6064-8.. PMID 1700279 DOI: 10.1128/mcb.10.11.6064  0.864
1989 Yarden Y, Weinberg RA. Experimental approaches to hypothetical hormones: detection of a candidate ligand of the neu protooncogene. Proceedings of the National Academy of Sciences of the United States of America. 86: 3179-83. PMID 2470093 DOI: 10.1073/Pnas.86.9.3179  0.671
1988 Yarden Y, Ullrich A. Molecular analysis of signal transduction by growth factors Biochemistry. 27: 3113-3119. PMID 3291942 DOI: 10.1021/Bi00409A001  0.389
1988 Yarden Y, Ullrich A. Growth factor receptor tyrosine kinases Annual Review of Biochemistry. 57: 443-478. PMID 3052279 DOI: 10.1146/Annurev.Bi.57.070188.002303  0.606
1988 Seger R, Yarden Y, Kashles O, Goldblatt D, Schlessinger J, Shaltiel S. The epidermal growth factor receptor as a substrate for a kinase-splitting membranal proteinase. The Journal of Biological Chemistry. 263: 3496-500. PMID 2830286  0.707
1987 Yarden Y, Schlessinger J. Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor. Biochemistry. 26: 1443-51. PMID 3494473 DOI: 10.1021/Bi00379A035  0.744
1987 Yarden Y, Schlessinger J. Self-phosphorylation of epidermal growth factor receptor: evidence for a model of intermolecular allosteric activation. Biochemistry. 26: 1434-42. PMID 3494472 DOI: 10.1021/Bi00379A034  0.754
1987 Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ, Chen E, Schlessinger J, Francke U, Ullrich A. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. The Embo Journal. 6: 3341-51. PMID 2448137 DOI: 10.1002/J.1460-2075.1987.Tb02655.X  0.722
1986 Ullrich A, Riedel H, Yarden Y, Coussens L, Gray A, Dull T, Schlessinger J, Waterfield MD, Parker PJ. Protein kinases in cellular signal transduction: tyrosine kinase growth factor receptors and protein kinase C. Cold Spring Harbor Symposia On Quantitative Biology. 51: 713-24. PMID 3472757 DOI: 10.1101/Sqb.1986.051.01.084  0.712
1986 Yarden Y, Escobedo JA, Kuang WJ, Yang-Feng TL, Daniel TO, Tremble PM, Chen EY, Ando ME, Harkins RN, Francke U. Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors. Nature. 323: 226-32. PMID 3020426 DOI: 10.1038/323226A0  0.537
1986 Yarden Y, Rodriguez H, Wong SKF, Brandt DR, May DC, Burnier J, Harkins RN, Chen EY, Ramachandran J, Ullrich A. The avian β-adrenergic receptor: Primary structure and membrane topology Proceedings of the National Academy of Sciences of the United States of America. 83: 6795-6799. PMID 3018746 DOI: 10.1073/Pnas.83.18.6795  0.406
1986 Zidovetzki R, Yarden Y, Schlessinger J, Jovin TM. Microaggregation of hormone-occupied epidermal growth factor receptors on plasma membrane preparations. The Embo Journal. 5: 247-50. PMID 3011399 DOI: 10.1002/J.1460-2075.1986.Tb04205.X  0.679
1985 Yarden Y, Schlessinger J. The EGF receptor kinase: evidence for allosteric activation and intramolecular self-phosphorylation. Ciba Foundation Symposium. 116: 23-45. PMID 3000707  0.718
1985 Yarden Y, Harari I, Schlessinger J. Purification of an active EGF receptor kinase with monoclonal antireceptor antibodies. The Journal of Biological Chemistry. 260: 315-9. PMID 2578126  0.703
1984 Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW, Lee J, Yarden Y, Libermann TA, Schlessinger J. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature. 309: 418-25. PMID 6328312 DOI: 10.1038/309418A0  0.682
1984 Downward J, Yarden Y, Mayes E, Scrace G, Totty N, Stockwell P, Ullrich A, Schlessinger J, Waterfield MD. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature. 307: 521-7. PMID 6320011 DOI: 10.1038/307521A0  0.749
1984 Libermann TA, Razon N, Bartal AD, Yarden Y, Schlessinger J, Soreq H. Expression of epidermal growth factor receptors in human brain tumors. Cancer Research. 44: 753-60. PMID 6318976  0.585
1984 Lax I, Bar-Eli M, Yarden Y, Libermann TA, Schlessinger J. Antibodies to two defined regions of the transforming protein pp60src interact specifically with the epidermal growth factor receptor kinase system. Proceedings of the National Academy of Sciences of the United States of America. 81: 5911-5. PMID 6207534 DOI: 10.1073/Pnas.81.19.5911  0.741
1983 Schlessinger J, Schreiber AB, Levi A, Lax I, Libermann T, Yarden Y. Regulation of cell proliferation by epidermal growth factor. Crc Critical Reviews in Biochemistry. 14: 93-111. PMID 6301752 DOI: 10.3109/10409238309102791  0.73
1983 Schreiber AB, Libermann TA, Lax I, Yarden Y, Schlessinger J. Biological role of epidermal growth factor-receptor clustering. Investigation with monoclonal anti-receptor antibodies. The Journal of Biological Chemistry. 258: 846-53. PMID 6296087  0.675
1983 Gooi HC, Schlessinger J, Lax I, Yarden Y, Libermann TA, Feizi T. Monoclonal antibody reactive with the human epidermal-growth-factor receptor recognizes the blood-group-A antigen. Bioscience Reports. 3: 1045-52. PMID 6198005 DOI: 10.1007/Bf01121031  0.623
1983 Hapgood J, Libermann TA, Lax I, Yarden Y, Schreiber AB, Naor Z, Schlessinger J. Monoclonal antibodies against epidermal growth factor receptor induce prolactin synthesis in cultured rat pituitary cells (GH3). Proceedings of the National Academy of Sciences of the United States of America. 80: 6451-5. PMID 6195656 DOI: 10.1073/Pnas.80.21.6451  0.732
1983 Yarden Y, Schlessinger J. Phosphoamino acid specificity of the EGF-receptor kinase system in normal mitogenically responsive human cells Cell Biology International Reports. 7: 533-534. DOI: 10.1016/0309-1651(83)90164-9  0.697
1982 Moolenaar WH, Yarden Y, de Laat SW, Schlessinger J. Epidermal growth factor induces electrically silent Na+ influx in human fibroblasts. The Journal of Biological Chemistry. 257: 8502-6. PMID 6979542  0.549
1982 Schlessinger J, Schreiber AB, Lax I, Yashuv-Gan Y, Libermann TA, Hillman GM, Levi A, Yarden Y. Molecular steps in the action and regulation of epidermal growth factor: a cellular mitogen. Progress in Clinical and Biological Research. 91: 359-72. PMID 6292947  0.614
1982 Yarden Y, Schreiber AB, Schlessinger J. A nonmitogenic analogue of epidermal growth factor induces early responses mediated by epidermal growth factor. The Journal of Cell Biology. 92: 687-93. PMID 6282891 DOI: 10.1083/Jcb.92.3.687  0.662
1981 Schreiber AB, Lax I, Yarden Y, Eshhar Z, Schlessinger J. Monoclonal antibodies against receptor for epidermal growth factor induce early and delayed effects of epidermal growth factor. Proceedings of the National Academy of Sciences of the United States of America. 78: 7535-9. PMID 6278478 DOI: 10.1073/Pnas.78.12.7535  0.693
1981 Zidovetzki R, Yarden Y, Schlessinger J, Jovin TM. Rotational diffusion of epidermal growth factor complexed to cell surface receptors reflects rapid microaggregation and endocytosis of occupied receptors. Proceedings of the National Academy of Sciences of the United States of America. 78: 6981-5. PMID 6273899 DOI: 10.1073/Pnas.78.11.6981  0.675
1981 Schreiber AB, Yarden Y, Schlessinger J. A non-mitogenic analogue of epidermal growth factor enhances the phosphorylation of endogenous membrane proteins. Biochemical and Biophysical Research Communications. 101: 517-23. PMID 6272761 DOI: 10.1016/0006-291X(81)91290-0  0.707
1981 Yarden Y, Gabbay M, Schlessinger J. Primary amines do not prevent the endocytosis of epidermal growth factor into 3T3 fibroblasts. Biochimica Et Biophysica Acta. 674: 188-203. PMID 6263349 DOI: 10.1016/0304-4165(81)90377-9  0.674
Show low-probability matches.